Vcanbio Cell & Gene Engineering Corp., Ltd (SHA:600645)

SHA:600645 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	1,465	1,550	1,538	1,507	1,497	1,288
Other Revenue	34.57	35.81	52.07	47.8	37.94	31.38
Revenue	1,500	1,585	1,590	1,555	1,535	1,319
Revenue Growth (YoY)	-5.92%	-0.27%	2.24%	1.27%	16.41%	-4.90%
Cost of Revenue	477.73	497.75	505.02	510.29	473.84	451.09
Gross Profit	1,022	1,088	1,085	1,045	1,061	867.81
Selling, General & Admin	678.48	695.33	719.77	723.4	749.78	632.71
Research & Development	170.16	182.11	184.49	146.12	133.85	111.78
Other Operating Expenses	21.78	19.39	19.19	17.59	16.54	15.49
Operating Expenses	900.64	924.48	946.57	901.67	937.05	774.3
Operating Income	121.15	163.2	138.14	142.93	124.44	93.51
Interest Expense	-4.51	-5.03	-5.02	-4.02	-3.14	-3.77
Interest & Investment Income	20.76	24.4	29.59	18.23	16.21	45.86
Earnings From Equity Investments	-14.3	-14.3	-11.85	-7.96	-	-
Currency Exchange Gain (Loss)	-0.97	-3.2	1.51	-2.37	0.1	2.04
Other Non Operating Income (Expenses)	-3.95	-3.22	1.03	-2	-1.49	-2.05
EBT Excluding Unusual Items	118.18	161.84	153.4	144.82	136.13	135.59
Impairment of Goodwill	-	-	-	-	-19.72	-264.65
Gain (Loss) on Sale of Investments	-25.49	-30.03	-36.09	-0.75	79.09	5.72
Gain (Loss) on Sale of Assets	0.08	1.3	3.67	2.03	0.51	20.4
Asset Writedown	-4.68	-4.68	-0.31	-0.8	-6.26	-
Other Unusual Items	8.46	7.52	11.92	9.9	33.2	13.84
Pretax Income	96.55	135.95	132.59	155.21	222.96	-89.09
Income Tax Expense	40.98	46.59	34.03	48.53	71.75	37.83
Earnings From Continuing Operations	55.57	89.35	98.55	106.68	151.21	-126.92
Minority Interest in Earnings	17.37	11	7.9	6.3	4.11	0.06
Net Income	72.94	100.35	106.45	112.99	155.32	-126.86
Net Income to Common	72.94	100.35	106.45	112.99	155.32	-126.86
Net Income Growth	-33.06%	-5.73%	-5.78%	-27.26%	-	-
Shares Outstanding (Basic)	442	456	463	471	471	470
Shares Outstanding (Diluted)	442	456	463	471	471	470
Shares Change (YoY)	-5.98%	-1.45%	-1.69%	0.02%	0.17%	4.01%
EPS (Basic)	0.17	0.22	0.23	0.24	0.33	-0.27
EPS (Diluted)	0.17	0.22	0.23	0.24	0.33	-0.27
EPS Growth	-28.80%	-4.35%	-4.17%	-27.27%	-	-
Free Cash Flow	259.72	217.87	210.4	162.7	193.22	152.64
Free Cash Flow Per Share	0.59	0.48	0.46	0.35	0.41	0.33
Gross Margin	68.14%	68.61%	68.23%	67.18%	69.14%	65.80%
Operating Margin	8.08%	10.29%	8.69%	9.19%	8.11%	7.09%
Profit Margin	4.86%	6.33%	6.70%	7.27%	10.12%	-9.62%
Free Cash Flow Margin	17.32%	13.74%	13.23%	10.46%	12.58%	11.57%
EBITDA	217.44	265.53	281.74	253.74	227.35	196.82
EBITDA Margin	14.50%	16.75%	17.72%	16.32%	14.81%	14.92%
D&A For EBITDA	96.29	102.33	143.6	110.81	102.91	103.31
EBIT	121.15	163.2	138.14	142.93	124.44	93.51
EBIT Margin	8.08%	10.29%	8.69%	9.19%	8.11%	7.09%
Effective Tax Rate	42.44%	34.27%	25.67%	31.26%	32.18%	-
Revenue as Reported	1,500	1,585	1,590	1,555	1,535	1,319
Advertising Expenses	-	30.86	32.98	29.02	32.43	26.79

Source: S&P Global Market Intelligence. Standard template. Financial Sources.